JP7885121B2 - 経口利尿薬に不応性の浮腫を処置するための方法及び組成物 - Google Patents

経口利尿薬に不応性の浮腫を処置するための方法及び組成物

Info

Publication number
JP7885121B2
JP7885121B2 JP2022533344A JP2022533344A JP7885121B2 JP 7885121 B2 JP7885121 B2 JP 7885121B2 JP 2022533344 A JP2022533344 A JP 2022533344A JP 2022533344 A JP2022533344 A JP 2022533344A JP 7885121 B2 JP7885121 B2 JP 7885121B2
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
bumetanide
use according
administration
subject
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2022533344A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023505189A5 (cg-RX-API-DMAC10.html
JP2023505189A (ja
Inventor
ラダクリシュナン，バラシンガム
エスケ，ベン
リン，ウェイ
チェン，アンドリュー，シャン
Original Assignee
レスク ファーマシューティカルズ エルエルシー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by レスク ファーマシューティカルズ エルエルシー filed Critical レスク ファーマシューティカルズ エルエルシー
Publication of JP2023505189A publication Critical patent/JP2023505189A/ja
Publication of JP2023505189A5 publication Critical patent/JP2023505189A5/ja
Priority to JP2025281644A priority Critical patent/JP2026076167A/ja
Application granted granted Critical
Publication of JP7885121B2 publication Critical patent/JP7885121B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0021—Intradermal administration, e.g. through microneedle arrays or needleless injectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cardiology (AREA)
  • Dermatology (AREA)
  • Physiology (AREA)
  • Otolaryngology (AREA)
  • Inorganic Chemistry (AREA)
  • Nutrition Science (AREA)
  • Diabetes (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Dispersion Chemistry (AREA)
  • Molecular Biology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
JP2022533344A 2019-12-04 2020-12-04 経口利尿薬に不応性の浮腫を処置するための方法及び組成物 Active JP7885121B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025281644A JP2026076167A (ja) 2019-12-04 2025-12-25 経口利尿薬に不応性の浮腫を処置するための方法及び組成物

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962943638P 2019-12-04 2019-12-04
US62/943,638 2019-12-04
PCT/US2020/063491 WO2021113775A1 (en) 2019-12-04 2020-12-04 Methods and compositions for treating edema refractory to oral diuretics

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025281644A Division JP2026076167A (ja) 2019-12-04 2025-12-25 経口利尿薬に不応性の浮腫を処置するための方法及び組成物

Publications (3)

Publication Number Publication Date
JP2023505189A JP2023505189A (ja) 2023-02-08
JP2023505189A5 JP2023505189A5 (cg-RX-API-DMAC10.html) 2023-12-12
JP7885121B2 true JP7885121B2 (ja) 2026-07-06

Family

ID=76209409

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022533344A Active JP7885121B2 (ja) 2019-12-04 2020-12-04 経口利尿薬に不応性の浮腫を処置するための方法及び組成物
JP2025281644A Pending JP2026076167A (ja) 2019-12-04 2025-12-25 経口利尿薬に不応性の浮腫を処置するための方法及び組成物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025281644A Pending JP2026076167A (ja) 2019-12-04 2025-12-25 経口利尿薬に不応性の浮腫を処置するための方法及び組成物

Country Status (10)

Country Link
US (5) US11123319B2 (cg-RX-API-DMAC10.html)
EP (1) EP4069222A4 (cg-RX-API-DMAC10.html)
JP (2) JP7885121B2 (cg-RX-API-DMAC10.html)
KR (1) KR20220113436A (cg-RX-API-DMAC10.html)
CN (1) CN115023223A (cg-RX-API-DMAC10.html)
AU (1) AU2020397176A1 (cg-RX-API-DMAC10.html)
BR (1) BR112022010879A2 (cg-RX-API-DMAC10.html)
CA (1) CA3160278A1 (cg-RX-API-DMAC10.html)
IL (1) IL293429A (cg-RX-API-DMAC10.html)
WO (1) WO2021113775A1 (cg-RX-API-DMAC10.html)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3160278A1 (en) 2019-12-04 2021-06-10 Balasingam Radhakrishnan Methods and compositions for treating edema refractory to oral diuretics
JP2024520788A (ja) * 2021-06-09 2024-05-24 レスク ファーマシューティカルズ エルエルシー 経口利尿薬に不応性の浮腫を処置するための皮下製剤及び方法
JP2024526357A (ja) * 2021-07-16 2024-07-17 ドリペル ビー．ブイ． 水性ブメタニド含有液体
IL313921A (en) * 2021-12-30 2024-08-01 Neuropro Therapeutics Inc Pharmaceutical composition
CN115645363B (zh) * 2022-10-31 2025-06-10 浙江普利药业有限公司 一种布美他尼注射液及其制备方法
WO2026017600A1 (en) 2024-07-15 2026-01-22 Dripel B.V. Aqueous bumetanide-containing liquid
WO2026043819A1 (en) * 2024-08-19 2026-02-26 Strategic Drug Solutions, Inc. Formulations and methods for convenient and rapid diuresis for the treatment of edema

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140128469A1 (en) 2011-05-10 2014-05-08 Concert Pharmaceuticals Inc. Deuterated n-butyl bumetanide
WO2019193161A1 (en) 2018-04-06 2019-10-10 Universität Wien Bumetanide derivatives for the therapy of stroke and other neurological diseases/disorders involving nkccs

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040105818A1 (en) 2002-11-26 2004-06-03 Alexza Molecular Delivery Corporation Diuretic aerosols and methods of making and using them
EP2389371A4 (en) * 2009-01-22 2012-09-12 Neurotherapeutics Pharma Inc ANALOGUES OF BUMETANIDE, FUROSEMIDE, PIRETANIDE, AZOSEMIDE AND TORSEMID, AND RELATED COMPOSITIONS AND METHODS OF USE
JP5914357B2 (ja) * 2010-01-15 2016-05-11 インセルム（インスティチュート ナショナル デ ラ サンテ エ デ ラ リシェルシェ メディカル） 自閉症の治療のための化合物
AU2012250050B2 (en) * 2011-04-28 2017-04-06 Platform Brightworks Two, Ltd. Improved parenteral formulations of lipophilic pharmaceutical agents and methods for preparing and using the same
US20150239832A1 (en) * 2012-09-04 2015-08-27 Neuro Pro Therapeutics, Inc. Analogs and prodrugs of loop diuretics, including bumetanide, furosemide and piretanide; compositions and methods of use
KR20160091348A (ko) * 2014-06-08 2016-08-02 오토텔릭 엘엘씨 부종없이 통증을 완화시키기 위한 고정된 용량의 복합제
CA3160278A1 (en) 2019-12-04 2021-06-10 Balasingam Radhakrishnan Methods and compositions for treating edema refractory to oral diuretics
JP2024520788A (ja) 2021-06-09 2024-05-24 レスク ファーマシューティカルズ エルエルシー 経口利尿薬に不応性の浮腫を処置するための皮下製剤及び方法

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140128469A1 (en) 2011-05-10 2014-05-08 Concert Pharmaceuticals Inc. Deuterated n-butyl bumetanide
WO2019193161A1 (en) 2018-04-06 2019-10-10 Universität Wien Bumetanide derivatives for the therapy of stroke and other neurological diseases/disorders involving nkccs

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
CrystEngComm，2012年，14，2428-2434

Also Published As

Publication number Publication date
US12150923B2 (en) 2024-11-26
WO2021113775A1 (en) 2021-06-10
AU2020397176A1 (en) 2022-06-30
CA3160278A1 (en) 2021-06-10
CN115023223A (zh) 2022-09-06
US20210169833A1 (en) 2021-06-10
US11260038B1 (en) 2022-03-01
US20220287996A1 (en) 2022-09-15
US20250268853A1 (en) 2025-08-28
KR20220113436A (ko) 2022-08-12
BR112022010879A2 (pt) 2022-10-18
US20250032436A1 (en) 2025-01-30
IL293429A (en) 2022-07-01
US12329731B2 (en) 2025-06-17
WO2021113775A8 (en) 2021-07-22
US11123319B2 (en) 2021-09-21
EP4069222A1 (en) 2022-10-12
EP4069222A4 (en) 2023-12-27
JP2026076167A (ja) 2026-05-11
US12558330B2 (en) 2026-02-24
JP2023505189A (ja) 2023-02-08

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20231204

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20231204

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20241120

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20241203

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20250225

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250603

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20250826

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20251225

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20260127

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20260526

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20260624

R150 Certificate of patent or registration of utility model

Ref document number: 7885121

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150